公开(公告)号：US20240358803A1

公开(公告)日：2024-10-31

申请号：US18767447

申请日：2024-07-09

申请人： Nutramax Laboratories, Inc.

发明人： Brian Cornblatt ,  Grace Cornblatt ,  Anton Bzhelyansky ,  Robert Henderson

IPC分类号： A61K38/47 ,  A23L33/105 ,  A61K9/00 ,  A61K9/14 ,  A61K9/28 ,  A61K31/19 ,  A61K31/194 ,  A61K31/26 ,  A61K31/357 ,  A61K31/375 ,  A61K31/7028 ,  A61K31/716 ,  A61K33/06 ,  A61K36/06 ,  A61K36/07 ,  A61K36/28 ,  A61K36/31 ,  A61K45/06 ,  A61K47/42 ,  A61P3/06

CPC分类号： A61K38/47 ,  A23L33/105 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/28 ,  A61K31/19 ,  A61K31/194 ,  A61K31/26 ,  A61K31/357 ,  A61K31/375 ,  A61K31/7028 ,  A61K31/716 ,  A61K33/06 ,  A61K36/06 ,  A61K36/07 ,  A61K36/28 ,  A61K36/31 ,  A61K45/06 ,  A61K47/42 ,  A61P3/06 ,  C12Y302/01147 ,  A23V2002/00

摘要： The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.

公开(公告)号：US12115173B2

公开(公告)日：2024-10-15

申请号：US17666964

申请日：2022-02-08

申请人： Elba Laboratories

发明人： Frank Dreher

IPC分类号： A61K31/616 ,  A61K31/192 ,  A61K31/194 ,  A61K31/20 ,  A61K31/375 ,  A61K31/60 ,  A61K47/32

CPC分类号： A61K31/616 ,  A61K31/192 ,  A61K31/194 ,  A61K31/20 ,  A61K31/375 ,  A61K31/60 ,  A61K47/32

摘要： The present disclosure generally relates to topical compositions comprising a combination of at least one alpha-hydroxy acid (e.g., glycolic acid) combined with at least one beta-hydroxy acid (e.g., salicylic acid) in the presence of water-soluble polystyrenes or appropriate salts thereof. The present disclosure further provides methods of making and using such compositions.

公开(公告)号：US20240315956A1

公开(公告)日：2024-09-26

申请号：US18574757

申请日：2022-07-08

申请人： US NANO FOOD & DRUG INC

发明人： Hing Sang PUI ,  Yip Ching PUI ,  Yip Shu PUI

IPC分类号： A61K9/46 ,  A61K9/00 ,  A61K31/194 ,  A61K31/4015 ,  A61K31/415 ,  A61K47/12 ,  A61K47/32 ,  A61K47/38

CPC分类号： A61K9/0007 ,  A61K9/0095 ,  A61K31/194 ,  A61K31/4015 ,  A61K31/415 ,  A61K47/12 ,  A61K47/32 ,  A61K47/38

摘要： The disclosure is directed to the method of production of the composition of a cyclooxygenase-2 (COX-2) inhibitor comprising a water soluble excipient comprising HPMC, an organic acid and one or more other components. The composition may be in the form of pellets, a tablet, a capsule or granules with higher dissolution of the API or fast disintegration in the aqueous medium. In some embodiments, the composition further contains a carbonate salt to form a weakly effervescent disintegration formulation.

公开(公告)号：US20240299471A1

公开(公告)日：2024-09-12

申请号：US18604196

申请日：2024-03-13

申请人： MarvelBiome, Inc.

发明人： Jothi Amaranath Govindan ,  Elamparithi Jayamani ,  Priti H. Chatter ,  Mukesh Chatter

IPC分类号： A61K35/747 ,  A61K31/132 ,  A61K31/19 ,  A61K31/194 ,  A61K31/198 ,  A61K31/205 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/4402 ,  A61K31/455 ,  A61K31/522 ,  A61K31/575 ,  A61K35/741 ,  A61K35/742 ,  A61K35/745 ,  A61P25/28

CPC分类号： A61K35/747 ,  A61K31/132 ,  A61K31/19 ,  A61K31/194 ,  A61K31/198 ,  A61K31/205 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/4402 ,  A61K31/455 ,  A61K31/522 ,  A61K31/575 ,  A61K35/741 ,  A61K35/742 ,  A61K35/745 ,  A61P25/28

摘要： Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or a combination thereof) for treating neurodegenerative diseases, disorders, and conditions are disclosed.

公开(公告)号：US12071397B2

公开(公告)日：2024-08-27

申请号：US17232729

申请日：2021-04-16

申请人： EVOLOGIE LLC

发明人： Gary I. Weinberger ,  H. Robert Nagel ,  Richard A. Brown

IPC分类号： C07C279/14 ,  A61K9/107 ,  A61K31/194 ,  A61K31/198 ,  A61K31/223 ,  A61K31/60 ,  A61K47/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/32

CPC分类号： C07C279/14 ,  A61K9/107 ,  A61K31/194 ,  A61K31/198 ,  A61K31/223 ,  A61K31/60 ,  A61K47/14 ,  A61K47/06 ,  A61K47/10 ,  A61K47/32 ,  A61K31/198 ,  A61K2300/00 ,  A61K31/194 ,  A61K2300/00 ,  A61K31/60 ,  A61K2300/00 ,  A61K31/223 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical compositions and methods useful for the treatment of dermatological disorders, and in particular acne vulgaris and skin pigmentation disorders. Pharmaceutical compositions comprising one or more arginine, salicylic acid and/or azelaic acid that are useful for the treatment of dermatological diseases and the symptoms and underlying causes of such dermatological diseases are also disclosed.

公开(公告)号：US12064443B2

公开(公告)日：2024-08-20

申请号：US18235867

申请日：2023-08-20

申请人： VANESSA RESEARCH, INC.

发明人： Dmitry Kravtsov ,  Norman Gray

IPC分类号： A61K31/7016 ,  A61K9/06 ,  A61K31/194 ,  A61K31/225 ,  A61K36/736 ,  A61K45/06 ,  A61P1/12

CPC分类号： A61K31/7016 ,  A61K9/06 ,  A61K31/194 ,  A61K31/225 ,  A61K36/736 ,  A61K45/06 ,  A61P1/12

摘要： A composition for the treatment of diarrheal and other diseases, comprising a reaction product of one or more polyphenol compound; sucralfate; and at least one acid.

公开(公告)号：US12064408B2

公开(公告)日：2024-08-20

申请号：US17326944

申请日：2021-05-21

申请人： The Children's Medical Center Corporation ,  The General Hospital Corporation

发明人： Umut Ozcan ,  Joseph Majzoub ,  Ralph Mazitschek

IPC分类号： A61K31/198 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/195 ,  A61K38/22 ,  A61K45/06 ,  A61P3/04

CPC分类号： A61K31/198 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/195 ,  A61K38/2264 ,  A61K45/06 ,  A61P3/04 ,  A61K31/192 ,  A61K2300/00 ,  A61K31/194 ,  A61K2300/00 ,  A61K31/195 ,  A61K2300/00 ,  A61K31/198 ,  A61K2300/00 ,  A61K38/2264 ,  A61K2300/00

摘要： Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.

公开(公告)号：US20240261322A1

公开(公告)日：2024-08-08

申请号：US18637767

申请日：2024-04-17

申请人： NOxy Health Products, Inc.

发明人： C. Michael Miller ,  Gordon K. Hill ,  A. John Pate ,  David A. Bell

IPC分类号： A61K33/00 ,  A61K9/00 ,  A61K9/12 ,  A61K31/19 ,  A61K31/194 ,  A61K31/375 ,  A61K47/12 ,  A61P17/00

CPC分类号： A61K33/00 ,  A61K9/0014 ,  A61K9/122 ,  A61K31/19 ,  A61K31/194 ,  A61K31/375 ,  A61P17/00 ,  A61K47/12

摘要： A topical application of nitric oxide may be provided by two separate containers, each containing an active component media to produce nitric oxide when combined. For example, a nitrite component media may be contained in one dispenser and an acidified component media may be contained in another dispenser. Each dispenser may dispense the respective component media as a foam. The resultant foams are combined to initiate the production of nitric oxide and the mixture of foams is applied topically to treat various skin disorders or wounds.

公开(公告)号：US20240252453A1

公开(公告)日：2024-08-01

申请号：US18565673

申请日：2022-01-27

申请人： QINGHAI SPRING MEDICINAL RESOURCES TECHNOLOGY CO.,LTD.

发明人： Xuefeng ZHANG ,  Guoxia MA

IPC分类号： A61K31/16 ,  A61K9/00 ,  A61K31/075 ,  A61K31/19 ,  A61K31/194 ,  A61K31/20 ,  A61K31/22 ,  A61K31/225 ,  A61K31/265 ,  A61P25/20

CPC分类号： A61K31/16 ,  A61K9/0095 ,  A61K31/075 ,  A61K31/19 ,  A61K31/194 ,  A61K31/20 ,  A61K31/22 ,  A61K31/225 ,  A61K31/265 ,  A61P25/20

摘要： A use of a composition of alcohol and a cooling agent in regulating a sexual function, protecting a cardiovascular and cerebrovascular system, promoting hepatocyte regeneration, fighting against a tumor, and improving the immunity and sleep quality, relating to the fields of medicine, and health care products and food. The components of the composition comprise: alcohol and a cooling agent. Moreover, the composition comprises an organic acid. In the composition, the content of alcohol is 1-99% vol, and the content of the cooling agent is 0.05-500 ppm. The composition can regulate the sexual function, protect the cardiovascular and cerebrovascular system, promote the hepatocyte regeneration, fight against the tumor, and improve the immunity and sleep quality within a short period.

公开(公告)号：US20240239735A1

公开(公告)日：2024-07-18

申请号：US18559891

申请日：2022-05-13

申请人： WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.

发明人： Liang WANG ,  Jun LOU ,  Yi YUAN ,  Xiaodan GUO ,  Yongkai CHEN ,  Yihan ZHANG ,  Huayun HONG ,  Wei PENG ,  Chaodong WANG

IPC分类号： C07C55/07 ,  A61K31/10 ,  A61K31/194 ,  A61K31/4155 ,  A61K45/06 ,  C07C51/43 ,  C07C57/145 ,  C07C59/255 ,  C07C315/06 ,  C07C317/14 ,  C07D403/04

CPC分类号： C07C55/07 ,  A61K31/10 ,  A61K31/194 ,  A61K31/4155 ,  A61K45/06 ,  C07C51/43 ,  C07C57/145 ,  C07C59/255 ,  C07C315/06 ,  C07C317/14 ,  C07D403/04 ,  C07B2200/13

摘要： An acid addition salt of a ROCK inhibitor, and a crystal form, a composition and the pharmaceutical use thereof are provided. The acid addition salt is an acid addition salt of compound A and any one of the following acids: hydrochloric acid, p-toluenesulfonic acid, benzenesulfonic acid, maleic acid, tartaric acid, oxalic acid, fumaric acid, sulfuric acid, methanesulfonic acid, phosphoric acid, succinic acid or citric acid (A). The acid addition salt of compound A and the crystal form thereof have the characteristics of high solubility, good stability, high purity, few impurities and high bioequivalence, and are beneficial for the storage, quality control and druggability of drugs.